Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
IsraelRecruitingPHASE2
Conditions
Crohn's Disease Relapse · Biological Substance; Adverse Effect
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Soroka University Medical Center, Beersheba, Israel
Contact: Study coordinator (Doron Schwartz, MD)Bnei Zion, Haifa, Israel
Contact: Study coordinator (Tova Rainis, MD)Carmel Medical Center, Haifa, Israel
Contact: Study coordinator (Ori Segol, MD)Rambam Health Care Campus, Haifa, Israel
Contact: Study coordinator (Haggai Bar-Yoseph, MD)Wolfson Medical Center, Holon, Israel
Contact: Study coordinator (Eran Israeli, MD)Hadassah Medical Center, Jerusalem, Israel
Contact: Study coordinator (Lior Katz, MD)Shaare Zedek, Jerusalem, Israel
Contact: Study coordinator (Ariella Shitrit, MD)Zvulun, Kiryat Bialik, Israel
Contact: Study coordinator (Reut Lutski, MD)Rabin Medical Center, Petah Tikva, Israel
Contact: Study coordinator (Iris Dotan)